Cassava’s Simufilam: Who to Believe—Wall Street or Alzheimer’s Researchers?
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the Charter…
Sponsored: This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the…
Some drug developers have put stock in the cholinergic hypothesis, developing a type of medication known as cholinesterase inhibitors. While Alzheimer’s still has no…
Researchers at the Salk Institute for Biological Studies have reported that a drug candidate called CMS121 has successfully halted and possibly reversed memory loss in…
Alzheimer’s Disease takes hundreds of thousands of lives every year, affecting 47 million people worldwide. But so far, no amount of urgency, nor billions…
About seven out of ten cases of Alzheimer’s are accompanied by symptoms of agitation and aggression. This could mean pacing, restlessness, shouting and screaming,…
Targeting beta-amyloid protein before symptoms of cognitive decline or Alzheimer’s appear is the goal of one trial out of the National Institute on Aging…
Whether it’s diet, exercise or air pollution, researchers are constantly investigating lifestyle and environmental factors that may play a role in the progression or…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
In a new study, scientists have tested an experimental drug in mice that may hold promise for future Alzheimer’s treatments. The drug involves a…
Biogen has agreed to buy an experimental Alzheimer’s and Parkinson’s treatment from Pfizer, the company announced Monday. In the agreed deal, Biogen will pay…